FDA approves talazoparib with enzalutamide for HRR-mutated hormone-sensitive metastatic prostate cancer
- On 26 October 2026 the FDA approved Talzenna (talazoparib) with enzalutamide for metastatic prostate cancer.
- The talazoparib approval covers androgen pathway modulation-naive or -sensitive disease with homologous recombination repair (HRR) gene mutations.
- In TALAPRO-3 (599 patients), talazoparib cut the risk of radiographic progression or death by about 52%.
- The talazoparib label includes warnings for myelodysplastic syndrome and bone marrow suppression.
The US Food and Drug Administration approved Pfizer's Talzenna (talazoparib) with enzalutamide on 26 October 2026 for adults with metastatic prostate cancer that is androgen pathway modulation-naive or -sensitive and carries homologous recombination repair (HRR) gene mutations detected by an FDA-authorized test.
Which mutations
Eligibility spans 12 genes, including BRCA1, BRCA2, ATM, CHEK2 and PALB2, so it is not limited to BRCA. The FDA previously approved the FoundationOne CDx and FoundationOne Liquid CDx assays to identify eligible patients.
Trial and results
Approval rests on TALAPRO-3, a randomized double-blind trial of 599 patients who received enzalutamide with either talazoparib or placebo, plus continuous androgen deprivation therapy. Median radiographic progression-free survival was not reached with talazoparib versus 45.8 months with placebo (hazard ratio 0.48). Overall survival data are immature.
Dose and warnings
The recommended dose is 0.5 mg by mouth once daily with enzalutamide. The label includes warnings for myelodysplastic syndrome/acute myeloid leukaemia, bone marrow suppression and harm to an unborn baby.
Sources: US Food and Drug Administration (FDA), Urology Times
This story is relayed from the source named above; responsibility for its content rests with the original source.
FAQ
What did the FDA approve for talazoparib?
On 26 October 2026 the FDA approved talazoparib (Talzenna) with enzalutamide for hormone-sensitive metastatic prostate cancer with HRR gene mutations.
Who is eligible for talazoparib with enzalutamide?
Talazoparib with enzalutamide is for adults with androgen pathway modulation-naive or -sensitive metastatic prostate cancer and a mutation in one of 12 HRR genes.
What did talazoparib show in TALAPRO-3?
In TALAPRO-3, talazoparib plus enzalutamide cut the risk of radiographic progression or death by about 52% (hazard ratio 0.48) versus enzalutamide alone.
What is the talazoparib dose for prostate cancer?
The recommended talazoparib dose is 0.5 mg by mouth once daily with enzalutamide, alongside androgen deprivation therapy.
What are the main warnings for talazoparib?
Talazoparib warnings include myelodysplastic syndrome/acute myeloid leukaemia, bone marrow suppression and embryo-fetal toxicity.



